Literature DB >> 25034377

Cerebrospinal fluid levels of Alzheimer's disease biomarkers in middle-aged patients with type 1 diabetes.

D Margriet Ouwens1, Eelco van Duinkerken, S Niki M Schoonenboom, Daniella Herzfeld de Wiza, Martin Klein, Larissa van Golen, Petra J W Pouwels, Frederik Barkhof, Annette C Moll, Frank J Snoek, Charlotte E Teunissen, Philip Scheltens, Michaela Diamant.   

Abstract

AIMS/HYPOTHESIS: Type 1 diabetes is associated with moderate cognitive decline and cerebral alterations and may lead to an increased risk of dementia, including Alzheimer's disease. This study aimed to investigate the levels of risk markers for Alzheimer's disease in middle-aged patients with type 1 diabetes and controls, and their potential associations with cognitive and cerebral measures.
METHODS: Levels of β-amyloid (Aβ) 42, Tau, phosphorylated Tau (pTau), the soluble form of low-density lipoprotein receptor-related protein 1 (sLRP1) and macrophage colony-stimulating factor (MCSF) were quantified by ELISA in serum and cerebrospinal fluid (CSF) collected from 37 patients with type 1 diabetes and 15 controls. Associations between biomarkers and determinants of cognitive function and white matter integrity were assessed using hierarchical regression analysis controlling for age, HbA1c and estimated intelligence quotient (IQ).
RESULTS: CSF levels of pTau, Aβ42 and LRP1 were higher in patients with type 1 diabetes than in controls (all p < 0.05). There was a trend towards increased Tau levels in patients with type 1 diabetes (p = 0.056), while CSF levels of MCSF were similar between patients with type 1 diabetes and controls. Regression analysis showed that elevated CSF sLRP1 levels were associated with better attention (β = 0.518; p = 0.002) and a better speed of information-processing (β = 0.368; p = 0.034), as well as increased integrity of the white matter of the right inferior fronto-occipital tract (β = 0.395; p = 0.022). Furthermore, elevated Tau levels were associated with decreased integrity of the white matter of right inferior fronto-occipital tract (β = -0.584; p = 0.002). CONCLUSIONS/
INTERPRETATION: CSF levels of biomarkers for Alzheimer's disease are altered in patients with type 1 diabetes compared with controls, but the observed profile does not match the profile characterising pre-Alzheimer's disease patients.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25034377     DOI: 10.1007/s00125-014-3333-6

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  26 in total

1.  CSF biomarkers and medial temporal lobe atrophy predict dementia in mild cognitive impairment.

Authors:  F H Bouwman; S N M Schoonenboom; W M van der Flier; E J van Elk; A Kok; F Barkhof; M A Blankenstein; Ph Scheltens
Journal:  Neurobiol Aging       Date:  2006-06-19       Impact factor: 4.673

2.  Association of the LRP1 gene and cognitive performance with amnestic mild cognitive impairment in elderly Chinese.

Authors:  Yong M Shi; Hong Zhou; Zhi J Zhang; Hui Yu; Feng Bai; Yong G Yuan; Ling L Deng; Jian P Jia
Journal:  Int Psychogeriatr       Date:  2009-08-10       Impact factor: 3.878

3.  Michaela Diamant, 11 April 1962-9 April 2014.

Authors:  Robert J Heine; Hannele Yki-Järvinen; Steven E Kahn; Daniel H van Raalte
Journal:  Diabetologia       Date:  2014-05-06       Impact factor: 10.122

4.  Cross-sectional and longitudinal relationships between cerebrospinal fluid biomarkers and cognitive function in people without cognitive impairment from across the adult life span.

Authors:  Ge Li; Steven P Millard; Elaine R Peskind; Jing Zhang; Chang-En Yu; James B Leverenz; Cynthia Mayer; Jane S Shofer; Murray A Raskind; Joseph F Quinn; Douglas R Galasko; Thomas J Montine
Journal:  JAMA Neurol       Date:  2014-06       Impact factor: 18.302

5.  Amyloid-beta peptide-receptor for advanced glycation endproduct interaction elicits neuronal expression of macrophage-colony stimulating factor: a proinflammatory pathway in Alzheimer disease.

Authors:  S Du Yan; H Zhu; J Fu; S F Yan; A Roher; W W Tourtellotte; T Rajavashisth; X Chen; G C Godman; D Stern; A M Schmidt
Journal:  Proc Natl Acad Sci U S A       Date:  1997-05-13       Impact factor: 11.205

6.  Joint effect of hypertension and APOE genotype on CSF biomarkers for Alzheimer's disease.

Authors:  Maartje I Kester; Wiesje M van der Flier; Gorana Mandic; Marinus A Blankenstein; Philip Scheltens; Majon Muller
Journal:  J Alzheimers Dis       Date:  2010       Impact factor: 4.472

7.  Amyloid-beta(1-42), total tau, and phosphorylated tau as cerebrospinal fluid biomarkers for the diagnosis of Alzheimer disease.

Authors:  Cees Mulder; Nicolaas A Verwey; Wiesje M van der Flier; Femke H Bouwman; Astrid Kok; Evert J van Elk; Philip Scheltens; Marinus A Blankenstein
Journal:  Clin Chem       Date:  2009-10-15       Impact factor: 8.327

Review 8.  Clearance of amyloid-beta peptide across the blood-brain barrier: implication for therapies in Alzheimer's disease.

Authors:  R Deane; R D Bell; A Sagare; B V Zlokovic
Journal:  CNS Neurol Disord Drug Targets       Date:  2009-03       Impact factor: 4.388

9.  Reduced O-GlcNAcylation links lower brain glucose metabolism and tau pathology in Alzheimer's disease.

Authors:  Fei Liu; Jianhua Shi; Hitoshi Tanimukai; Jinhua Gu; Jianlan Gu; Inge Grundke-Iqbal; Khalid Iqbal; Cheng-Xin Gong
Journal:  Brain       Date:  2009-05-18       Impact factor: 13.501

10.  Increased tau phosphorylation and cleavage in mouse models of type 1 and type 2 diabetes.

Authors:  Bhumsoo Kim; Carey Backus; Sangsu Oh; John M Hayes; Eva L Feldman
Journal:  Endocrinology       Date:  2009-10-09       Impact factor: 4.736

View more
  13 in total

1.  Importance of Treatment Status in Links Between Type 2 Diabetes and Alzheimer's Disease.

Authors:  Elissa C McIntosh; Daniel A Nation
Journal:  Diabetes Care       Date:  2019-03-04       Impact factor: 19.112

2.  Peripheral Levels of AGEs and Astrocyte Alterations in the Hippocampus of STZ-Diabetic Rats.

Authors:  Patrícia Nardin; Caroline Zanotto; Fernanda Hansen; Cristiane Batassini; Manuela Sangalli Gasparin; Patrícia Sesterheim; Carlos-Alberto Gonçalves
Journal:  Neurochem Res       Date:  2016-04-15       Impact factor: 3.996

3.  Network-based analysis on genetic variants reveals the immunological mechanism underlying Alzheimer's disease.

Authors:  Pan Guo; Changying Cao; Yuequn Ma; Ju Wang
Journal:  J Neural Transm (Vienna)       Date:  2021-04-28       Impact factor: 3.575

4.  Disrupted subject-specific gray matter network properties and cognitive dysfunction in type 1 diabetes patients with and without proliferative retinopathy.

Authors:  Eelco van Duinkerken; Richard G Ijzerman; Martin Klein; Annette C Moll; Frank J Snoek; Philip Scheltens; Petra J W Pouwels; Frederik Barkhof; Michaela Diamant; Betty M Tijms
Journal:  Hum Brain Mapp       Date:  2015-12-23       Impact factor: 5.038

Review 5.  The diabetic brain and cognition.

Authors:  Peter Riederer; Amos D Korczyn; Sameh S Ali; Ovidiu Bajenaru; Mun Seong Choi; Michael Chopp; Vesna Dermanovic-Dobrota; Edna Grünblatt; Kurt A Jellinger; Mohammad Amjad Kamal; Warda Kamal; Jerzy Leszek; Tanja Maria Sheldrick-Michel; Gohar Mushtaq; Bernard Meglic; Rachel Natovich; Zvezdan Pirtosek; Martin Rakusa; Melita Salkovic-Petrisic; Reinhold Schmidt; Angelika Schmitt; G Ramachandra Sridhar; László Vécsei; Zyta Beata Wojszel; Hakan Yaman; Zheng G Zhang; Tali Cukierman-Yaffe
Journal:  J Neural Transm (Vienna)       Date:  2017-08-01       Impact factor: 3.575

6.  Soluble Megalin is Reduced in Cerebrospinal Fluid Samples of Alzheimer's Disease Patients.

Authors:  Carlos Spuch; Desireé Antequera; Consuelo Pascual; Soledad Abilleira; María Blanco; María José Moreno-Carretero; Jesús Romero-López; Tetsuya Ishida; Jose Antonio Molina; Alberto Villarejo; Felix Bermejo-Pareja; Eva Carro
Journal:  Front Cell Neurosci       Date:  2015-04-15       Impact factor: 5.505

Review 7.  Can insulin signaling pathways be targeted to transport Aβ out of the brain?

Authors:  Milene Vandal; Philippe Bourassa; Frédéric Calon
Journal:  Front Aging Neurosci       Date:  2015-06-16       Impact factor: 5.750

8.  Type 2 diabetes mellitus and cerebrospinal fluid Alzheimer's disease biomarker amyloid β1-42 in Alzheimer's Disease Neuroimaging Initiative participants.

Authors:  Wei Li; Shannon L Risacher; Sujuan Gao; Stephen L Boehm; Jeffrey S Elmendorf; Andrew J Saykin
Journal:  Alzheimers Dement (Amst)       Date:  2017-11-23

9.  Docosahexaenoic Acid Increases the Potency of Soluble Epoxide Hydrolase Inhibitor in Alleviating Streptozotocin-Induced Alzheimer's Disease-Like Complications of Diabetes.

Authors:  Rohit Pardeshi; Nityanand Bolshette; Kundlik Gadhave; Mohammad Arfeen; Sahabuddin Ahmed; Rohitash Jamwal; Bruce D Hammock; Mangala Lahkar; Sumanta Kumar Goswami
Journal:  Front Pharmacol       Date:  2019-04-24       Impact factor: 5.810

10.  Changes in Cerebrospinal Fluid Tau and β-Amyloid Levels in Diabetic and Prediabetic Patients: A Meta-Analysis.

Authors:  Yanhui Lu; Xinjun Jiang; Shuling Liu; Mingzi Li
Journal:  Front Aging Neurosci       Date:  2018-10-11       Impact factor: 5.750

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.